Aging blood stem cells weaken immunity. Latest research shows drugs and reprogramming can restore their function, promising healthier aging. New research reveals that aging blood stem cells can be pha...
A 2023 study in the Journal of Cachexia, Sarcopenia and Muscle finds rapamycin reduces muscle protein synthesis after exercise in older adults, highlighting trade-offs in longevity strategies. Recent ...
A new multi-phase clinical trial on rapamycin aims to establish safe dosing for anti-aging, bridging the gap between off-label use and scientific validation in longevity medicine. Recent advancements ...
Analyzing recent rapamycin clinical trials for anti-aging, focusing on optimal dosing, safety, and the shift from off-label use to evidence-based protocols in longevity research. New human trials on r...
ARPA-H’s PROSPR program directs over $50 million to aging trials, advancing drugs like Cambrian’s rapamycin analog and Linnaeus’s GPER-targeter, signaling a shift in treating aging a...
Recent studies show mTOR inhibitors like rapamycin reduce DNA damage and senescence in immune cells, offering a new approach to enhance healthy aging and combat age-related immune decline. New researc...
Explore the science of autophagy, its role in cellular health, and its connection to longevity and disease prevention. Learn how fasting, exercise, and nutrients like spermidine can enhance this proce...